ArticleFuture science OA2026

Dapagliflozin for attenuating early anthracycline-associated cardiac changes (DAPA-AIC): a randomized, double-blind, placebo-controlled trial.

Hakar Abdulkareem Saeed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.